+10%

est. 2Y upside i

HealthcareSeries B

An online provider for greater mental health

Rank

#3289

Sector

Digital Mental Health

Est. Liquidity

~4Y

Data Quality

Data: Low

Meru Health has real institutional revenue ($17.9M) and blue-chip payer partnerships, but the equity math is difficult over a 2-year window: the last funding round was 4+ years ago with zero IPO or M&A signals, an estimated ~$120M valuation implies a severe preference stack that consumes ~46 cents of every exit dollar before common shareholders participate, and growth rate data is absent.

Last updated: May 5, 2026

Bull (18%)+130%

A major payer or health system (e.g., Cigna, CVS Health, UnitedHealth) acquires Meru at ~$270M (roughly 15x ~$18M revenue) within 3 years, driven by accelerating teen market expansion and value-based contract wins. After $55.4M in liquidation preferences, preferred shareholders convert pro-rata and common holders realize ~2.25x on estimated $120M entry valuation.

Base (47%)+20%

Meru sustains payer relationships and grows revenue to $22–25M by 2027, ultimately raising a Series C at $145–160M — a modest step-up from the estimated $120M current valuation. The 2-year horizon yields limited liquidity; paper gains are real but largely unrealized common equity.

Bear (35%)-65%

Digital mental health consolidation favors better-capitalized rivals (Lyra Health, Spring Health), forcing a flat or down round at $70–85M; at $80M, the $55.4M preference stack consumes ~69% of proceeds, leaving common equity worth roughly one-third of current grant value. A distressed sale or runway exhaustion produces similar outcomes.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

46%

Total funding of $55.4M against an estimated current valuation of ~$120M implies liquidation preferences consume approximately 46% of equity value before common shareholders receive proceeds.

Dilution Risk

high

No profitability signal at $17.9M revenue with 55% gross margins strongly suggests the company will need at least one more dilutive round before any liquidity event, further eroding common equity percentage.

Secondary Liquidity

none

No secondary market, tender offer, or platform activity has been noted; shares are effectively illiquid until a formal exit event.

Other — 4 roles

View all 4 open roles at Meru Health →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Meru Health's data — designed to show you've done your homework.

  • 1

    “You put 100% of fees at risk in your value-based contracts — what does gross margin look like per program cohort after clinical and therapist costs, and what retention rate triggers a full fee?”

  • 2

    “Revenue is $17.9M roughly four years post-Series B; what does the payer contract pipeline look like today, and why has the growth trajectory been more measured than typical venture-backed digital health peers?”

  • 3

    “What is the current 409A valuation and common stock FMV, and has there been any secondary market activity or tender offer for employee equity since the 2021 raise?”

Community

Valuation Sentiment

Our model estimates +10% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.